Verrica Pharmaceuticals Inc. Stockholders Equity

Quick Answer

Verrica Pharmaceuticals Inc. reported Stockholders Equity of $24.74 million for fiscal year 2025.

Verrica Pharmaceuticals Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $24.74M +350.9%
2024 -$9.86M -149.9%
2023 $19.76M -50.6%
2022 $40.03M +22.8%
2021 $32.60M -1.2%
2020 $32.99M -49.3%
2019 $65.02M -27.3%
2018 $89.43M +1370.1%
2017 -$7.04M -164.3%
2016 -$2.66M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 -$17.04M +50.0% +2.5%
June 30, 2025 -$17.48M -31.5% +5.9%
March 31, 2025 -$18.58M -1331.8% -88.4%
December 31, 2024 -$9.86M -149.9% +71.0%
September 30, 2024 -$34.05M -180.5% -156.0%
June 30, 2024 -$13.30M -124.0% -982.0%
March 31, 2024 $1.51M -97.7% -92.4%
December 31, 2023 $19.76M -50.6% -53.3%
  • Verrica Pharmaceuticals Inc. showed an increase of +350.9% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2016–2025 period, Verrica Pharmaceuticals Inc.’s stockholders equity has grown by 1028.8% (from -$2.66 million to $24.74 million).
  • The most recent figure is from Verrica Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment